Agnes Mwakingwe-Omari

408 total citations
8 papers, 53 citations indexed

About

Agnes Mwakingwe-Omari is a scholar working on Epidemiology, Infectious Diseases and Dermatology. According to data from OpenAlex, Agnes Mwakingwe-Omari has authored 8 papers receiving a total of 53 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 2 papers in Infectious Diseases and 2 papers in Dermatology. Recurrent topics in Agnes Mwakingwe-Omari's work include Herpesvirus Infections and Treatments (7 papers), Hepatitis B Virus Studies (2 papers) and SARS-CoV-2 and COVID-19 Research (2 papers). Agnes Mwakingwe-Omari is often cited by papers focused on Herpesvirus Infections and Treatments (7 papers), Hepatitis B Virus Studies (2 papers) and SARS-CoV-2 and COVID-19 Research (2 papers). Agnes Mwakingwe-Omari collaborates with scholars based in Belgium, United States and India. Agnes Mwakingwe-Omari's co-authors include Desmond Curran, Nicolas Lecrenier, Brett Leav, Jacqueline M. Miller, Jyoti Soni, Ji-Young Min, Ginette Girard, Thomas Breuer, Harry Seifert and Dagna Constenla and has published in prestigious journals such as Clinical Infectious Diseases, The Journal of Infectious Diseases and Annals of the Rheumatic Diseases.

In The Last Decade

Agnes Mwakingwe-Omari

7 papers receiving 53 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Agnes Mwakingwe-Omari Belgium	4	46	11	9	9	8	8	53
Jaynier Moya United States	3	37 0.8×	12 1.1×	9 1.0×	7 0.8×	14 1.8×	4	59
Joan Paul United States	5	12 0.3×	18 1.6×	5 0.6×	3 0.3×	20 2.5×	7	46
David Butuk Belgium	2	23 0.5×	4 0.4×	3 0.3×	2 0.2×	10 1.3×	2	29
Lina Pérez–Breva Spain	2	45 1.0×	23 2.1×	15 1.7×	1 0.1×	7 0.9×	4	50
Stefanie Sammet Germany	5	22 0.5×	6 0.5×	4 0.4×		19 2.4×	14	43
Nicole Toursarkissian Germany	2	26 0.6×	8 0.7×	2 0.2×		4 0.5×	2	26
Vesna Hadžiosmanović Bosnia and Herzegovina	3	14 0.3×	8 0.7×			6 0.8×	4	40
Meghan Weinberg United States	4	32 0.7×	4 0.4×		4 0.4×	20 2.5×	7	43
Tian Liu China	4	28 0.6×	10 0.9×		9 1.0×	8 1.0×	7	46
Kelsey Jacobson United States	5	26 0.6×	4 0.4×	4 0.4×	2 0.2×	9 1.1×	6	68

Countries citing papers authored by Agnes Mwakingwe-Omari

Since Specialization

Citations

This map shows the geographic impact of Agnes Mwakingwe-Omari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Agnes Mwakingwe-Omari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Agnes Mwakingwe-Omari more than expected).

Fields of papers citing papers by Agnes Mwakingwe-Omari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Agnes Mwakingwe-Omari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Agnes Mwakingwe-Omari. The network helps show where Agnes Mwakingwe-Omari may publish in the future.

Co-authorship network of co-authors of Agnes Mwakingwe-Omari

This figure shows the co-authorship network connecting the top 25 collaborators of Agnes Mwakingwe-Omari. A scholar is included among the top collaborators of Agnes Mwakingwe-Omari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Agnes Mwakingwe-Omari. Agnes Mwakingwe-Omari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Constenla, Dagna, et al.. (2025). Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases. The Journal of Infectious Diseases. 232(6). e931–e940. 1 indexed citations

Constenla, Dagna, et al.. (2024). P986 Effectiveness of the adjuvanted recombinant zoster vaccine (RZV) in preventing herpes zoster (HZ) among patients ≥50 years of age with Inflammatory Bowel Disease in the United States: A retrospective real-world database analysis from 2018 to 2021. Journal of Crohn s and Colitis. 18(Supplement_1). i1779–i1780.

Seifert, Harry, et al.. (2024). No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial. Human Vaccines & Immunotherapeutics. 20(1). 2327736–2327736. 8 indexed citations

Constenla, Dagna, et al.. (2024). POS1476-HPR THE ADJUVANTED RECOMBINANT ZOSTER VACCINE IS EFFECTIVE IN PATIENTS ≥50 YEARS OF AGE WITH RHEUMATOID ARTHRITIS AT INCREASED RISK OF HERPES ZOSTER: RESULTS FROM A REAL-WORLD DATABASE ANALYSIS IN THE UNITED STATES FROM 2018 TO 2021. Annals of the Rheumatic Diseases. 83. 1189–1189. 1 indexed citations

Leav, Brett, et al.. (2023). No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial. Clinical Infectious Diseases. 77(9). 1238–1246. 6 indexed citations

Mwakingwe-Omari, Agnes, et al.. (2023). Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies. Human Vaccines & Immunotherapeutics. 19(3). 2278362–2278362. 21 indexed citations

Strezova, Ana, et al.. (2022). 114. Long-term Protection Against Herpes Zoster (HZ) by the Adjuvanted Recombinant Zoster Vaccine (RZV): Interim Efficacy, Immuno and Safety Results at Approximately 10 Years after Initial Vaccination. Open Forum Infectious Diseases. 9(Supplement_2). 3 indexed citations

Min, Ji-Young, et al.. (2021). The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial. Journal of Infection. 84(4). 490–498. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact